Pharmacological Treatments for Borderline Personality Disorder
For carers supporting someone with Borderline Personality Disorder, one of the most common and difficult questions is whether medication really helps. Many people with BPD are prescribed antidepressants, antipsychotics, mood stabilisers, or a combination of several drugs. Families often hope these treatments will bring stability and relief. Yet a major 2021 systematic review published in CNS Drugs gives a much more cautious picture. Looking across 21 randomised controlled trials involving 1,768 participants, the review found that medications do not appear to meaningfully improve the core features of BPD. Some drugs may slightly reduce specific symptoms in some people, but overall the evidence is weak, inconsistent, and far less reassuring than prescribing patterns might suggest.
Medication is widely used, but the evidence is disappointing
For many carers, medication becomes part of the BPD story very early. A loved one may be given something for low mood, anxiety, agitation, sleep problems, or emotional instability. Over time, one medication may be swapped for another, or several may be used together. This can create the impression that medicines are a standard and effective treatment for Borderline Personality Disorder itself.
The review discussed here challenges that assumption. It found that although medications are commonly prescribed, the evidence that they help the core features of BPD is limited. Across the trials included in the review, pharmacological treatments did not show consistent reductions in the overall severity of the disorder.
That is an important finding. It means that while medication may sometimes affect particular symptoms around the edges, it does not appear to transform the deeper difficulties that define BPD, such as unstable identity, fear of abandonment, chaotic relationships, and long-standing emotional dysregulation.
For carers, this can explain a common experience: a person may seem slightly calmer, sleep a little better, or feel less sharply distressed for a period, but the core patterns in relationships, self-image, and coping may remain largely unchanged.
The review suggests that medication may sometimes soften certain symptoms, but it does little to change the core psychological features of BPD.
Only a small number of drugs had been properly studied
One striking part of the review is how little good-quality research exists compared with how often drugs are used in practice. The authors found trials on only nine medications, even though 87 different drugs are reportedly used in clinical settings with people who have BPD.
That gap matters. It means prescribing has expanded far beyond the evidence base. In real life, people may be taking medications for which there is little or no reliable trial evidence in BPD populations. Families may assume there is strong science behind these decisions, when in many cases that is not true.
The trials that were included focused mainly on three broad classes of medication: second-generation antipsychotics, anticonvulsants or mood stabiliser-type drugs, and antidepressants. Even within those classes, the number of studies was limited, and the results were often inconsistent.
So before even looking at what the review found, there is already an important message: medication use in BPD has raced ahead of solid evidence. That should encourage caution, realistic expectations, and careful discussion with prescribers.
Second-generation antipsychotics showed only limited benefit
Second-generation antipsychotics were the most studied drug class in the review. These drugs were found to offer a small benefit for general psychiatric symptoms, but not for the core traits of BPD itself. In other words, they may have helped some people feel somewhat less distressed in a broad sense, but they did not clearly improve the underlying patterns that make BPD so painful and disruptive.
This distinction is very important. A person may look slightly more settled on the surface, but still struggle with unstable relationships, identity confusion, emotional volatility, or chronic interpersonal pain. Families can easily mistake symptom dulling for deeper recovery, especially when they are desperate for signs of progress.
The review also noted that side effects were common. These included weight gain, sedation, and dry mouth. Adherence was low, and in some trials up to 68% of participants dropped out. That tells us something very practical: even when a medication might offer a small benefit, many people do not continue taking it, perhaps because the drawbacks outweigh the gains.
For carers, this may help explain why a loved one may start medication with hope and then stop it, resist it, or seem no better despite taking it. The issue is not always unwillingness. Sometimes the treatment simply does not help enough to justify what it costs physically or emotionally.
Antipsychotic medication may slightly reduce general distress in some people, but the review found little evidence that it changes the central features of BPD.
Anticonvulsants showed some promise, but the evidence was thin
The review found that anticonvulsants such as lamotrigine and topiramate showed some possible benefit for symptoms like irritability and emotional lability. This may sound encouraging, especially for carers who see how quickly mood and emotional tone can shift in BPD.
However, the evidence was described as thin and inconsistent. The apparent benefits came from a small number of studies, and the certainty of the evidence was low or very low. That means we cannot be confident that these results are strong, stable, or likely to apply across wider groups of people.
This is an important reminder not to over-read positive findings. It is common in mental health research for isolated studies to suggest benefit, only for later evidence to show that the effect is smaller, less reliable, or more limited than first thought.
For carers, this means these medications may sometimes help with certain emotional symptoms, but they should not be understood as proven or dependable solutions for BPD as a whole. A prescription may be reasonable in a specific case, but it should be viewed as a tentative measure, not a cure or a central long-term answer.
Antidepressants did not show convincing benefit
Antidepressants are among the most commonly prescribed psychiatric drugs, so many carers assume they must also have a clear role in BPD. Yet the review found remarkably little evidence to support that idea. Only one published study of fluoxetine met the inclusion criteria, and it showed no significant benefit over placebo.
This does not mean antidepressants are never useful. A person with BPD may also have depression or anxiety, and an antidepressant may be prescribed for those symptoms. But the review suggests that antidepressants should not be assumed to treat the core structure of Borderline Personality Disorder itself.
That distinction matters a great deal. Sometimes medication is prescribed for overlapping symptoms, and families understandably assume it is treating BPD. In reality, it may only be targeting a separate mood or anxiety problem, and even then with mixed success.
If carers know this, they are in a better position to ask clear questions. What exactly is this medication meant to help with? Is it for depression, anxiety, sleep, or agitation? Or is it being used because no other support is available right now? Those questions matter because clear expectations reduce confusion and disappointment.
Antidepressants may sometimes be prescribed around BPD, but the review found no convincing evidence that they improve the core disorder itself.
Why medication is still prescribed so often
If the evidence is so weak, why are medications used so commonly in BPD? The review suggests part of the answer lies in clinical habit, and part lies in desperation. In overstretched services, medication may become the easiest or only thing available in the short term.
For clinicians working with limited time and limited access to therapy, writing a prescription can feel more possible than arranging specialist psychological care that may involve long waits, strict criteria, or no local provision at all. In that context, prescribing something may seem better than doing nothing.
Families often find themselves caught in that same difficult reality. They may know that medication is not solving the deeper problem, but therapy is unavailable, delayed, or inconsistent. So medication becomes the default offer, not because it is ideal, but because the system has few better options ready to hand.
Understanding this helps carers see that the issue is not always bad faith or poor intention. Often it is a sign of a system trying to manage serious suffering with limited tools. But even understandable stopgaps can still create problems when they are presented as more effective than the evidence supports.
Polypharmacy is a serious concern
One of the most worrying points raised in the review is the frequency of overmedication. Nearly one in five patients with BPD were reported to be taking four or more psychotropic drugs. This kind of polypharmacy increases the risk of side effects, drug interactions, and long-term health complications.
For carers, this often feels painfully familiar. A loved one may start with one medication, then receive another to manage side effects, another to help with sleep, another for mood, and another during crisis. Over time, it can become difficult to know which drug is doing what, whether anything is truly helping, or whether the overall burden has become part of the problem.
Polypharmacy can also make ordinary life harder. Sedation, weight gain, blunting, restlessness, poor concentration, and emotional flattening may all interfere with functioning. A person may become less active, less motivated, or less emotionally available, and families may struggle to tell whether this is illness, medication effect, or both.
This is why the review’s message is so important. Prescribing is not neutral. Medication is not a harmless placeholder. Even when used with good intentions, it can create significant costs that need to be weighed carefully against uncertain benefit.
When several psychiatric medications are used together, the risks rise sharply, while the evidence that this improves BPD remains weak.
The research itself has major gaps
The review does not only tell us that the evidence is weak. It also shows why. Most of the trials were small, short in duration, and limited in who they included. Many excluded people with co-occurring conditions such as PTSD or substance use disorders, even though those conditions are very common in real people with BPD.
This means the studies often did not reflect the complex cases carers are dealing with in everyday life. Real-world BPD rarely appears in a neat, uncomplicated form. People often have trauma histories, mood symptoms, anxiety, self-harm, substance difficulties, or other diagnoses. Yet many of the trials excluded exactly those people.
Adolescents were missing entirely from the trials. Nearly all participants were white and female, which raises further concerns about generalisability. On top of that, none of the studies examined long-term recovery or quality of life in a meaningful way.
So the evidence is not only limited in strength. It is also limited in relevance. It does not fully tell us what medication does for the broad, diverse, and often highly complex population of people who actually live with BPD.
Medication did not improve social or occupational functioning
One of the most practically important findings is that no medication showed consistent benefit in improving social or occupational functioning. This means there was no reliable evidence that drug treatment helped people manage work, study, relationships, or everyday life better in a lasting way.
That matters because these are the areas that often matter most to families. Carers are not only hoping for fewer symptoms on a rating scale. They are hoping their loved one can cope better, relate more safely, sustain education or work, and build a life that feels more stable.
If medication does not reliably improve those wider outcomes, then its role becomes much narrower than many people assume. It may help soften a specific symptom for some people, but it is not the main route to recovery.
For carers, this can be clarifying. If a medication is being used, it helps to know that the real work of recovery is still likely to depend on emotional learning, relationships, coping skills, and psychologically informed support rather than the prescription itself.
No medication in the review showed consistent benefit for helping people with BPD function better in work, study, or relationships.
This fits with current NICE guidance
The findings of the review align with current guidance from the National Institute for Health and Care Excellence. NICE is clear that medication should not be used as the primary treatment for Borderline Personality Disorder. Instead, the recommended approach is psychological treatment.
Therapies such as Dialectical Behaviour Therapy, Mentalisation-Based Treatment, and Structured Clinical Management are more in keeping with what BPD actually is: a condition rooted in emotional regulation, self-image, attachment, coping, and relationships. These are not areas that tablets are well designed to change.
The difficulty, of course, is that these therapies require time, trust, trained professionals, and consistent delivery. Many families cannot access them quickly. Waiting lists can be long, and some services offer only fragments of what is needed.
So carers often end up in a painful position. The evidence-based answer points toward therapy, but the system may offer medication first because it is easier to provide. Knowing this can help families push for the right kind of support, even when the path to it is slow.
What carers can realistically do
Carers need a practical position in the middle of all this uncertainty. One helpful starting point is to understand clearly what medication can and cannot do. Some medications may help with anxiety, sleep, agitation, or other specific problems. For some people, that may be useful. But it is important not to expect medication to resolve the core personality dynamics, attachment pain, or emotional patterns at the heart of BPD.
It is also important to keep communication open with prescribers. Families may need to ask what the target symptom is, how success will be measured, what side effects to watch for, and when a medication should be reviewed. These are not hostile questions. They are part of safe and thoughtful care.
Monitoring side effects matters greatly, especially when multiple drugs are involved. Weight changes, sedation, emotional blunting, restlessness, or reduced functioning should not be dismissed automatically. They need to be noticed and discussed.
At the same time, carers need support beyond the medical conversation. Living alongside BPD is exhausting, and many families are expected to carry enormous responsibility without enough guidance. Education, peer support, and psychologically informed strategies can make a measurable difference in how families cope and how crises are handled.
Medication may sometimes have a limited place, but carers still need knowledge, review, and realistic expectations if they are to navigate BPD safely.
The bigger message is about the kind of help BPD really needs
Perhaps the clearest lesson from this review is that Borderline Personality Disorder cannot be meaningfully reduced to a prescribing problem. The condition is deeply relational and psychological. It affects how people feel, how they understand themselves, how they relate to others, and how they respond to stress and abandonment.
That is why recovery usually depends on sustained, psychologically grounded support. People need help learning emotional regulation, developing safer coping strategies, understanding relationship patterns, and building a more stable sense of self. These are long-term tasks, and they require more than medication.
For carers, this can be strangely validating. Many families already sense that the answers will not be found in a prescription pad alone. They see that medication may change the surface without reaching the centre. The review confirms that this intuition is often correct.
That does not make the situation easy. But it does make it clearer. The goal is not to reject medication blindly. It is to place it in its proper, limited context and keep attention on the forms of support that are more likely to make a lasting difference.
Conclusion
The 2021 systematic review in CNS Drugs offers the clearest answer so far to a question many carers ask: do medications help Borderline Personality Disorder? The answer is cautious and sobering. Although medications are widely prescribed, the evidence suggests they do little to improve the core features of BPD. Some drugs may offer small benefits for specific symptoms in some people, but these effects are limited, inconsistent, and often supported by low-certainty evidence.
The review also raises serious concerns about overmedication, side effects, and the gap between everyday prescribing practice and the actual evidence base. It shows that medication is often used in a context where psychological therapies are difficult to access, even though those therapies remain the recommended primary treatment.
For carers, the message is both difficult and clarifying. Medication may sometimes play a small supporting role, but it is not the main answer to BPD. Real recovery is more likely to come from sustained, relational, and psychologically informed support, together with education, patience, and proper help for families themselves.
In that sense, the review confirms what many carers already know from lived experience: healing from BPD requires far more than symptom control. It requires understanding, structure, therapeutic work, and time.
The evidence suggests that medication is at most a limited support in BPD. The real work of recovery lies in psychological treatment, relationships, and long-term support.
Source note
This article is based on the following systematic review:
Stoffers-Winterling, J., et al. (2021). Pharmacological treatments for borderline personality disorder: A systematic review and meta-analysis. CNS Drugs.
Read the full review here: https://link.springer.com/article/10.1007/s40263-021-00844-4